Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:ENZY
- CUSIP: N/A
- Web: www.enzymotec.com
- Market Cap: $184.7 million
- Outstanding Shares: 22,944,000
- 50 Day Moving Avg: $8.54
- 200 Day Moving Avg: $7.87
- 52 Week Range: $5.20 - $9.32
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 15.19
- P/E Growth: 1.76
- Annual Revenue: $47.7 million
- Price / Sales: 3.87
- Book Value: $5.98 per share
- Price / Book: 1.35
- EBIDTA: ($386,999.00)
- Net Margins: 4.82%
- Return on Equity: 1.95%
- Return on Assets: 1.78%
- Current Ratio: 7.40%
- Quick Ratio: 5.00%
- Average Volume: 12,026 shs.
- Beta: 1.26
- Short Ratio: 6.91
Frequently Asked Questions for Enzymotec Ltd (NASDAQ:ENZY)
What is Enzymotec Ltd's stock symbol?
Enzymotec Ltd trades on the NASDAQ under the ticker symbol "ENZY."
How were Enzymotec Ltd's earnings last quarter?
Enzymotec Ltd (NASDAQ:ENZY) posted its quarterly earnings data on Wednesday, May, 17th. The company reported $0.03 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.06 by $0.03. The firm had revenue of $12 million for the quarter, compared to analyst estimates of $14.23 million. Enzymotec Ltd had a return on equity of 1.95% and a net margin of 4.82%. The company's quarterly revenue was down 14.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.09 earnings per share. View Enzymotec Ltd's Earnings History.
Where is Enzymotec Ltd's stock going? Where will Enzymotec Ltd's stock price be in 2017?
2 equities research analysts have issued 12-month price targets for Enzymotec Ltd's stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Enzymotec Ltd's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for Enzymotec Ltd.
What are analysts saying about Enzymotec Ltd stock?
Here are some recent quotes from research analysts about Enzymotec Ltd stock:
- 1. According to Zacks Investment Research, "Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. " (5/22/2017)
- 2. Jefferies Group LLC analysts commented, "Enzymotec has been pressured by a shifting regulatory environment and lackluster demand even as it has accelerated investment in Vaya. Regulatory changes will continue to ripple through the supply chain in 2H17-2018. We expect shares to remain range-bound absent an improvement in end markets and sustained profitability in Vaya. Clarity around strategic opportunities in InFat and the pending CEO transition would help reduce its risk profile." (2/23/2017)
Who are some of Enzymotec Ltd's key competitors?
Some companies that are related to Enzymotec Ltd include BioSpecifics Technologies Corp. (BSTC), Pacific Biosciences of California (PACB), Agenus (AGEN), Advaxis (ADXS), ChemoCentryx (CCXI), Corbus Pharmaceuticals Holdings (CRBP), Nantkwest (NK), GlycoMimetics (GLYC), Concert Pharmaceuticals (CNCE), Edge Therapeutics (EDGE), Ocular Therapeutix (OCUL), XBiotech (XBIT), Novavax (NVAX), Ignyta (RXDX), Veracyte (VCYT), SIGA Technologies (SIGA), Dynavax Technologies (DVAX) and Nabriva Therapeutics AG - (NBRV).
Who owns Enzymotec Ltd stock?
Enzymotec Ltd's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Paulson & CO. Inc. (18.33%), Janus Capital Management LLC (1.26%), Renaissance Technologies LLC (1.26%), Acadian Asset Management LLC (1.03%), California Public Employees Retirement System (0.68%) and FMR LLC (0.37%). View Institutional Ownership Trends for Enzymotec Ltd.
Who sold Enzymotec Ltd stock? Who is selling Enzymotec Ltd stock?
Who bought Enzymotec Ltd stock? Who is buying Enzymotec Ltd stock?
Enzymotec Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Geode Capital Management LLC and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for Enzymotec Ltd.
How do I buy Enzymotec Ltd stock?
Shares of Enzymotec Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Enzymotec Ltd stock cost?
One share of Enzymotec Ltd stock can currently be purchased for approximately $8.05.
Earnings History for Enzymotec Ltd (NASDAQ:ENZY)Earnings History by Quarter for Enzymotec Ltd (NASDAQ:ENZY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/17/2017||3/31/2017||$0.06||$0.03||$14.23 million||$12.00 million||View||N/A|
|2/22/2017||Q416||$0.03||($0.10)||$11.47 million||$10.60 million||View||N/A|
|11/16/2016||Q316||$0.07||$0.03||$13.29 million||$11.40 million||View||N/A|
|8/9/2016||Q216||$0.08||$0.04||$14.90 million||$15.00 million||View||N/A|
|5/19/2016||Q116||$0.05||$0.09||$13.85 million||$14.00 million||View||Listen|
|2/17/2016||Q415||$0.10||$0.07||$14.01 million||$13.30 million||View||Listen|
|11/11/2015||Q315||$0.07||$0.08||$14.21 million||$12.40 million||View||Listen|
|8/12/2015||Q215||$0.06||$0.11||$12.39 million||$13.40 million||View||Listen|
|5/7/2015||Q115||$0.06||$0.09||$12.10 million||$12.25 million||View||N/A|
|2/18/2015||Q414||$0.08||$0.06||$11.11 million||$10.80 million||View||N/A|
|11/13/2014||Q314||$0.04||$0.05||$10.22 million||$9.50 million||View||N/A|
|8/5/2014||Q214||$0.10||$0.02||$14.88 million||$11.50 million||View||N/A|
|5/14/2014||Q114||$0.17||$0.24||$19.40 million||$23.70 million||View||N/A|
|2/13/2014||Q413||$0.11||$0.15||$11.64 million||$18.51 million||View||N/A|
|11/11/2013||Q313||$0.11||$0.13||$13.10 million||$22.50 million||View||Listen|
Earnings Estimates for Enzymotec Ltd (NASDAQ:ENZY)
Current Year EPS Consensus Estimate: $0.26 EPS
Next Year EPS Consensus Estimate: $0.53 EPS
Dividend History for Enzymotec Ltd (NASDAQ:ENZY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Enzymotec Ltd (NASDAQ:ENZY)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Enzymotec Ltd (NASDAQ:ENZY)
Latest Headlines for Enzymotec Ltd (NASDAQ:ENZY)
Enzymotec Ltd (ENZY) Chart for Wednesday, May, 24, 2017